Free Trial
NASDAQ:IVA

Inventiva (IVA) Stock Price, News & Analysis

Inventiva logo
$3.38 -0.12 (-3.43%)
Closing price 05/2/2025 03:54 PM Eastern
Extended Trading
$3.51 +0.13 (+3.85%)
As of 05/2/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Inventiva Stock (NASDAQ:IVA)

Key Stats

Today's Range
$3.30
$3.73
50-Day Range
$2.75
$3.89
52-Week Range
$1.53
$4.05
Volume
31,870 shs
Average Volume
63,125 shs
Market Capitalization
$177.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.40
Consensus Rating
Moderate Buy

Company Overview

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Inventiva Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

IVA MarketRank™: 

Inventiva scored higher than 36% of companies evaluated by MarketBeat, and ranked 725th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Inventiva has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Inventiva has only been the subject of 3 research reports in the past 90 days.

  • Read more about Inventiva's stock forecast and price target.
  • Earnings Growth

    Earnings for Inventiva are expected to grow in the coming year, from ($2.08) to ($1.85) per share.

  • Percentage of Shares Shorted

    1.13% of the float of Inventiva has been sold short.
  • Short Interest Ratio / Days to Cover

    Inventiva has a short interest ratio ("days to cover") of 27.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Inventiva has recently increased by 18.88%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Inventiva does not currently pay a dividend.

  • Dividend Growth

    Inventiva does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.13% of the float of Inventiva has been sold short.
  • Short Interest Ratio / Days to Cover

    Inventiva has a short interest ratio ("days to cover") of 27.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Inventiva has recently increased by 18.88%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Inventiva has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Inventiva this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for IVA on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Inventiva insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    32.00% of the stock of Inventiva is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 19.06% of the stock of Inventiva is held by institutions.

  • Read more about Inventiva's insider trading history.
Receive IVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter.

IVA Stock News Headlines

Inventiva (NASDAQ:IVA) Stock Price Up 3.2% - What's Next?
Elon Musk is all in on these robots …
Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang said, "The ChatGPT moment for robotics is right around the corner." In fact, I believe these robots could impact 65 million Americans lives — this year. And one stock — currently priced around $7 — could be the biggest winner.
Inventiva price target lowered to $9 from $12 at Guggenheim
See More Headlines

IVA Stock Analysis - Frequently Asked Questions

Inventiva's stock was trading at $2.14 at the beginning of the year. Since then, IVA shares have increased by 57.9% and is now trading at $3.38.
View the best growth stocks for 2025 here
.

Inventiva (IVA) raised $103 million in an IPO on Friday, July 10th 2020. The company issued 7,500,000 shares at $13.68 per share. Jefferies, Stifel and Guggenheim Securities served as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.

Inventiva's top institutional investors include Wealth Enhancement Advisory Services LLC (0.02%).

Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Inventiva investors own include Kinross Gold (KGC), Outlook Therapeutics (OTLK), Accuray (ARAY), Carnival Co. & (CCL), Alibaba Group (BABA), PayPal (PYPL).

Company Calendar

Today
5/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IVA
Fax
N/A
Employees
100
Year Founded
2011

Price Target and Rating

Average Stock Price Target
$10.40
High Stock Price Target
$17.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+207.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$9.20 million
Price / Cash Flow
N/A
Book Value
($0.67) per share
Price / Book
-5.04

Miscellaneous

Free Float
35,684,000
Market Cap
$177.37 million
Optionable
Not Optionable
Beta
0.84

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:IVA) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners